FDA seeks safety data for Lilly's oral GLP-1 Foundayo The FDA may have approved Eli Lilly's oral weight-loss drug Foundayo in record time, but it still needs to see more safety data including for liver and cardiovascular side effects
For benefits leaders sifting through the growing range of GLP-1 offerings, here are three considerations to shape your strategy: How can your GLP-1 benefits package reflect the diverse needs of your population
Shapeshift focuses on tightening and contouring the neck and jawline
- Pregnancy and breast-feeding: As there is no established safety data for MOTS-c use during pregnancy or breast-feeding, it should be avoided
Fiber adds bulk to stool, absorbs water, and helps regulate bowel movementsall crucial functions for those experiencing GLP-1-related digestive changes
Jump to: How digestion changes | How Mounjaro works | Managing side effects | Recognising bile acid diarrhoea | What to eat | Getting enough healthy fat | Eating well with a reduced appetite | Building movement habits | When to speak to your GP | Mounjaro clinical data | Frequently asked questions | Take home message You can take Mounjaro after gallbladder removal
